This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lacourciere, Y. Articles by Tancrede, G. Search for Related Content PubMed PubMed Citation Articles by Lacourciere, Y. Articles by Tancrede, G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CAPTOPRIL HYDROCHLOROTHIAZIDE METOPROLOL Medline Plus Health Information High Blood Pressure

Hypertension, Vol 21, 786-794, Copyright © 1993 by American Heart Association

ARTICLES

Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis

Y Lacourciere, A Nadeau, L Poirier and G Tancrede
Hypertension Research Unit, CHUL Research Center, Centre Hospitalier de l'Universite Laval, Ste-Foy, Quebec, Canada.

The effects of long-term treatment with captopril and conventional therapy on albuminuria and metabolic parameters were compared in 74 hypertensive type II diabetics with normal serum creatinine. Patients were treated double-blind with either captopril monotherapy or combined with hydrochlorothiazide or therapy with metoprolol, hydrochlorothiazide, or both for 36 months. The treatment was titrated to achieve goal diastolic blood pressure of < or = 85 mm Hg. The reductions in blood pressures during treatment were similar in patients with (n = 21) and without (n = 53) microalbuminuria treated with either captopril or conventional therapy. No significant changes in albuminuria occurred in normoalbuminuric patients with either therapy. Although albuminuria fell in nearly all patients with microalbuminuria treated with captopril, it rose in eight of 12 patients on conventional therapy, with macroalbuminuria developing in two of them. Renal function was preserved by both types of treatment in both patient groups. Long-term treatment with either conventional therapy or captopril did not alter metabolic variables. We conclude that captopril alone or in combination decreases albuminuria and prevents the development of macroalbuminuria in hypertensive type II diabetics with persistent microalbuminuria. The renoprotective effect of this agent, however, remains to be demonstrated with longer term data on renal function. Aggressive antihypertensive treatment with either captopril or conventional therapy appears to be effective in preventing the onset of microalbuminuria in most normoalbuminuric patients. In contrast, with previous short-term studies, the use of converting enzyme inhibitors or conventional therapy did not cause adverse metabolic effects.

This article has been cited by other articles:

				F. Persson, P. Rossing, P. Hovind, C. D.A. Stehouwer, C. Schalkwijk, L. Tarnow, and H.-H. Parving Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria: An IRMA 2 Substudy Diabetes, December 1, 2006; 55(12): 3550 - 3555. [Abstract] [Full Text] [PDF]

				G. L. Bakris, V. Fonseca, R. E. Katholi, J. B. McGill, F. Messerli, R. A. Phillips, P. Raskin, J. T. Wright Jr, B. Waterhouse, M. A. Lukas, et al. Differential Effects of {beta}-Blockers on Albuminuria in Patients With Type 2 Diabetes Hypertension, December 1, 2005; 46(6): 1309 - 1315. [Abstract] [Full Text] [PDF]

				M. Rahman, S. Pressel, B. R. Davis, C. Nwachuku, J. T. Wright Jr, P. K. Whelton, J. Barzilay, V. Batuman, J. H. Eckfeldt, M. Farber, et al. Renal Outcomes in High-Risk Hypertensive Patients Treated With an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs a Diuretic: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Arch Intern Med, April 25, 2005; 165(8): 936 - 946. [Abstract] [Full Text] [PDF]

				A. H. Barnett, S. C. Bain, P. Bouter, B. Karlberg, S. Madsbad, J. Jervell, J. Mustonen, and the Diabetics Exposed to Telmisartan and Enalapril Angiotensin-Receptor Blockade versus Converting-Enzyme Inhibition in Type 2 Diabetes and Nephropathy N. Engl. J. Med., November 4, 2004; 351(19): 1952 - 1961. [Abstract] [Full Text] [PDF]

				A. J. Palmer, L. Annemans, S. Roze, M. Lamotte, P. Lapuerta, R. Chen, S. Gabriel, P. Carita, R. A. Rodby, D. de Zeeuw, et al. Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive Medications Excluding ACE Inhibitors, Other Angiotensin-2 Receptor Antagonists, and Dihydropyridine Calcium Channel Blockers) or Late Irbesartan Treatment in Patients With Type 2 Diabetes, Hypertension, and Renal Disease Diabetes Care, August 1, 2004; 27(8): 1897 - 1903. [Abstract] [Full Text] [PDF]

				T. Berl Angiotensin-Converting Enzyme Inhibitors versus AT1 Receptor Antagonist in Cardiovascular and Renal Protection: The case for AT1 Receptor Antagonist J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S71 - 76. [Abstract] [Full Text]

				S. Andersen, J. Brochner-Mortensen, and H.-H. Parving Kidney Function During and After Withdrawal of Long-Term Irbesartan Treatment in Patients With Type 2 Diabetes and Microalbuminuria Diabetes Care, December 1, 2003; 26(12): 3296 - 3302. [Abstract] [Full Text] [PDF]

				L. M Ruilope, J. Segura, and E. L Schiffrin Review: ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients? Journal of Renin-Angiotensin-Aldosterone System, June 1, 2003; 4(2): 74 - 79. [Abstract] [PDF]

				S. Vijan and R. A. Hayward Treatment of Hypertension in Type 2 Diabetes Mellitus: Blood Pressure Goals, Choice of Agents, and Setting Priorities in Diabetes Care Ann Intern Med, April 1, 2003; 138(7): 593 - 602. [Abstract] [Full Text] [PDF]

				A. D. Mooradian Cardiovascular Disease in Type 2 Diabetes Mellitus: Current Management Guidelines Arch Intern Med, January 13, 2003; 163(1): 33 - 40. [Abstract] [Full Text] [PDF]

				K. F. Hilgers and J. F. E. Mann ACE Inhibitors versus AT1 Receptor Antagonists in Patients with Chronic Renal Disease J. Am. Soc. Nephrol., April 1, 2002; 13(4): 1100 - 1108. [Full Text] [PDF]

				H.-H. Parving, H. Lehnert, J. Brochner-Mortensen, R. Gomis, S. Andersen, P. Arner, and the Irbesartan in Patients with Type 2 Diabetes an The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes N. Engl. J. Med., September 20, 2001; 345(12): 870 - 878. [Abstract] [Full Text] [PDF]

				P. Huston and R. Peterson Withholding Proven Treatment in Clinical Research N. Engl. J. Med., September 20, 2001; 345(12): 912 - 914. [Full Text] [PDF]

				J. I. Barzilay, C. L. Jones, B. R. Davis, J. N. Basile, D. C. Goff Jr., J. O. Ciocon, M. E. Sweeney, and O. S. Randall Baseline Characteristics of the Diabetic Participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Diabetes Care, April 1, 2001; 24(4): 654 - 658. [Abstract] [Full Text]

				D. D. Maki, J. Z. Ma, T. A. Louis, and B. L. Kasiske Long-term Effects of Antihypertensive Agents on Proteinuria and Renal Function Arch Intern Med, May 22, 1995; 155(10): 1073 - 1080. [Abstract] [PDF]